Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neurizon Therapeutics.
RELATED STOCKHEAD STORIES
News
Closing Bell: ASX choppy as traders sit it out; BPM soars on Mt Gibson gold find
Health & Biotech
PharmAust seeks orphan drug designation in Europe for monepantel to treat ALS
Health & Biotech
Morgans sees big upside for PharmAust if monepantel succeeds
Health & Biotech
PharmAust reports positive interim results of OLE study on monepantel to treat ALS
Health & Biotech
ASX Health Stocks: Actinogen skyrockets 125pc on antidepressant drug trial results
Investor Guides
Investor Guide: Health & Biotech FY2025 featuring Tim Boreham
Health & Biotech
ScoPo’s Powerplays: ASX health stocks up in ‘fairly lacklustre week’
News
ASX Small Caps Lunch Wrap: The ASX is all red after a night to forget for US tech
Health & Biotech
PharmAust raises $7.8 million in hot SPP
Health & Biotech
PharmAust’s monepantel drug hits strategic milestone with selection for prestigious ALS treatment trial
Health & Biotech
ScoPo’s Powerplays: ASX health stocks hit resistance in first week of FY25
Stockhead TV
Break it Down: PharmAust cashes up for the fight against MND
Health & Biotech
PharmAust raises $10m as share price soars 100pc year to date
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Tech, Energy weigh down ASX; Schrole up almost 200pc on acquisition deal
News
ASX Small Caps Lunch Wrap: Which European food-babies just can’t handle the heat this week?
Health & Biotech
